Acadia Pharmaceuticals develops and commercializes innovative therapies for neurological and rare diseases, including the first FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome. Our focus is on harnessing scientific advancements to address critical needs in underserved patient communities, while expanding our pipeline to target conditions like Alzheimer’s disease psychosis and Lewy body dementia.
